Valuation: FamiCord AG

Market Cap 50.73M 58.35M 47.22M 43.35M 81.86M 5.57B 83.13M 557M 218M 2.77B 219M 214M 9.3B P/E 2026 *
291x
P/E 2027 * 48.5x
Enterprise Value 58.73M 67.56M 54.66M 50.19M 94.77M 6.45B 96.24M 644M 253M 3.21B 254M 248M 10.77B EV / Sales 2026 *
0.69x
EV / Sales 2027 * 0.64x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 day+2.48%
1 week+3.28%
1 month-18.17%
1 week 2.64
Extreme 2.643
2.76
1 month 2.62
Extreme 2.6225
3.17
Current year 2.62
Extreme 2.6225
3.5
1 year 2.62
Extreme 2.6225
3.5
3 years 2.62
Extreme 2.6225
3.5
5 years 2.62
Extreme 2.6225
3.5
10 years 2.62
Extreme 2.6225
3.5
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2022
Director of Finance/CFO 53 01/08/2024
Chief Tech/Sci/R&D Officer - 01/03/2025
Director TitleAgeSince
Chairman 62 28/06/2017
Director/Board Member - 01/01/2017
Director/Board Member 54 01/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
+2.48%+3.28% - - 58.35M
-0.75%-3.07%+67.17%+41.22% 133B
+1.72%+5.34%+12.78%+47.00% 87.16B
-0.80%+1.64%+8.35%+55.23% 28.85B
-0.55%+2.26%+36.38%+73.11% 25.72B
-0.21%+9.02%-10.56%-17.60% 21.9B
+0.81%+9.25%+61.16%+231.83% 20.51B
+0.51%+1.98%+73.38%+134.49% 15.41B
+0.64%+3.77%+6.91%-2.45% 14.98B
+0.36%+2.73%+2.70%-5.47% 13.55B
Average +0.42%+3.68%+28.70%+61.93% 40.15B
Weighted average by Cap. +0.13%+1.88%+37.46%+53.68%

Financials

2026 *2027 *
Net sales 85M 97.78M 79.12M 72.64M 137M 9.33B 139M 933M 366M 4.65B 367M 359M 15.58B 88.4M 102M 82.28M 75.54M 143M 9.71B 145M 970M 381M 4.83B 382M 374M 16.21B
Net income 300K 345K 279K 256K 484K 32.94M 492K 3.29M 1.29M 16.4M 1.3M 1.27M 54.99M 1M 1.15M 931K 855K 1.61M 110M 1.64M 10.97M 4.31M 54.67M 4.32M 4.23M 183M
Net Debt 8M 9.2M 7.45M 6.84M 12.91M 879M 13.11M 87.77M 34.45M 437M 34.56M 33.8M 1.47B 6M 6.9M 5.58M 5.13M 9.68M 659M 9.83M 65.83M 25.84M 328M 25.92M 25.35M 1.1B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
723
Date Price Change
31/07/26 CHF 2.709 +2.48%
30/07/26 CHF 2.643 -0.56%
29/07/26 CHF 2.658 -2.62%
28/07/26 CHF 2.730 -1.23%
27/07/26 CHF 2.764 +5.38%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.910EUR
Average target price
6.500EUR
Spread / Average Target
+123.37%

Annual profits - Rate of surprise